Eli Lilly disclosed a two‑pronged expansion strategy: a $1.2 billion plant in Puerto Rico to produce oral GLP‑1 candidate orforglipron and an alliance with Nvidia to build a massive AI supercomputer for drug discovery. The moves combine manufacturing scale for a fast‑growing metabolic franchise with investments in compute to accelerate discovery and development. The Puerto Rico facility is dedicated to orforglipron to boost oral GLP‑1 capacity and reduce supply bottlenecks for weight‑loss and metabolic drugs. Separately, Lilly and Nvidia said they will collaborate to create one of the most powerful in‑house systems in pharma to train large AI models for molecular design and translational biology. The strategy signals how top drugmakers are marrying production capacity with AI‑driven R&D to control supply and shorten pipelines. Competitors, CMOs and cloud providers will track how Lilly deploys compute to improve target ID, lead optimization and preclinical triage.